日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer

蛋白磷酸酶 2A 作为小细胞肺癌的治疗靶点

Tamara Mirzapoiazova, Gang Xiao, Bolot Mambetsariev, Mohd W Nasser, Emily Miaou, Sharad S Singhal, Saumya Srivastava, Isa Mambetsariev, Michael S Nelson, Arin Nam, Amita Behal, Leonidas Arvanitis, Pranita Atri, Markus Muschen, François L H Tissot, James Miser, John S Kovach, Martin Sattler, Surinder

Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease

滤泡外CD4+结核分枝杆菌的相互作用足以诱发自身免疫样慢性移植物抗宿主病。

Ruishu Deng ,Christian Hurtz ,Qingxiao Song ,Chanyu Yue ,Gang Xiao ,Hua Yu ,Xiwei Wu ,Markus Muschen ,Stephen Forman ,Paul J Martin ,Defu Zeng

Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia

靶向酪蛋白激酶 II 可恢复 Ikaros 肿瘤抑制因子活性并证明对高危白血病具有治疗效果

Chunhua Song, Chandrika Gowda, Xiaokang Pan, Yali Ding, Yongqing Tong, Bi-Hua Tan, Haijun Wang, Sunil Muthusami, Zheng Ge, Mansi Sachdev, Shantu G Amin, Dhimant Desai, Krishne Gowda, Raghavendra Gowda, Gavin P Robertson, Hilde Schjerven, Markus Muschen, Kimberly J Payne, Sinisa Dovat

Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia

ROR1 与前 B 细胞受体之间的串扰促进 t(1;19) 急性淋巴细胞白血病的存活

Vincent T Bicocca, Bill H Chang, Behzad Kharabi Masouleh, Markus Muschen, Marc M Loriaux, Brian J Druker, Jeffrey W Tyner

HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo

HDAC 抑制剂在体外和体内增强 BCR/ABL 激酶抑制剂 KW-2449 在伊马替尼敏感或耐药的 BCR/ABL+ 白血病细胞中的活性

Tri Nguyen, Yun Dai, Elisa Attkisson, Lora Kramer, Nicholas Jordan, Nguyen Nguyen, Nikhil Kolluri, Markus Muschen, Steven Grant